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Aims: The 6-min walking distance is often used for assessing the exercise capacity under the treatment with an
endothelin receptor antagonist (ERA) in patients with chronic thromboembolic pulmonary hypertension
(CTEPH). The cardiopulmonary exercise testing (CPX) was reported to be more useful for the patients with
pulmonary arterial hypertension (PAH), however, few reports exist in patients with inoperable CTEPH. The
aim of this study was to investigate the effects of an oral dual ERA, bosentan, on exercise capacity using CPX in
patients with PAH and inoperable CTEPH.
Main methods: This study included all patients diagnosed with 17 PAH and 12 CTEPH in the World Health
Organization functional classes II–IV who started treatment with bosentan therapy. They underwent CPX,
which was performed before bosentan therapy and at 3 to 6 months of the treatment.
Key ﬁndings: In PAH patients, peak VO2 signiﬁcantly increased after the bosentan treatment (p= 0.009). On the
other hand, in CTEPH patients, there were no signiﬁcant differences in the peak VO2. However, the peak PETCO2
was signiﬁcantly increased from 23.9 ± 5.2 mm Hg at baseline to 29.3 ± 10.7 mm Hg after the bosentan
treatment (p= 0.040). In addition, peakheart rate during exercise tended to decrease after the bosentan therapy
(p = 0.089).
Signiﬁcance:Bosentan therapy improved peak PETCO2 but not peakVO2 in patientswith inoperable CTEPH. These
ﬁndings demonstrated that CPX is useful for assessing the exercise capacity of patients with PAH and inoperable
CTEPH under the treatment with an ERA.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Patients with both pulmonary arterial hypertension (PAH) and
chronic thromboembolic pulmonary hypertension (CTEPH) have a
poor prognosis (Jenkins et al., 2012; Thenappan et al., 2010). Although
recent advances in medical therapy have improved the prognosis of
PAH patients (Galie et al., 2009), the effects of various drugs are limitedMedicine in Cardiopulmonary
, 65 Tsurumai-cho, Shouwa-ku,
o).
. This is an open access article underdepending on the severity of the underlying pulmonary vasculopathy
and resulting in right heart failure (Shah et al., 2009).
The 6-min walking distance (6MWD) is often used for assessing
the exercise capacity under the treatment of PAH speciﬁc drugs in
these patients. However, a more accurate exercise test could be recom-
mended to evaluate the exercise capacity of these patients. Cardiopul-
monary exercise testing (CPX) was reported to be more useful for
patients with PAH (Wensel et al., 2002). However, few reports exist in
patients with inoperable CTEPH (Zhai et al., 2011). Hoeper et al.
proposed a so called “goal-oriented treatment” using CPX or 6MWD
for PAH patients (Hoeper et al., 2005b). However, the 6MWD depends
not only on the cardiopulmonary function, but also on other factors,
including age, sex, muscularity, body weight and height (Enright andthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/)
Table 1
Baseline characteristics.
PAH (n = 17) CTEPH (n = 12) p
Age (years) 46 ± 21 49 ± 11 0.598
Male, n (%) 5 (30) 3 (25) 0.793
BMI (kg/m2) 21.3 ± 2.9 25.6 ± 4.1 0.005
IPAH/CTD/PPH/CHD, n 7/6/2/2
WHO I/II/III/IV, n 0/1/11/5 0/1/10/1 0.581
Medication
Diuretics 7 (47) 3 (25) 0.609
Ca antagonists 5 (29) 2 (17) 0.960
Statins 2 (12) 1 (8) 0.999
Laboratory
Plasma BNP (pg/mL) 187 (49–105) 101 (39–105) 0.286
UA (mg/dL) 6.6 ± 2.6 6.8 ± 2.3 0.899
Hemoglobin (g/dL) 14.7 ± 3.4 15.4 ± 1.3 0.618
eGFR (mL/min/1.73 m2) 81.2 ± 25.4 73.4 ± 20.6 0.420
T. chol (mg/dL) 179.5 ± 37.1 196.4 ± 43.6 0.341
Triglyceride (mg/dL) 125.2 ± 76.3 137.9 ± 34.9 0.610
HbA1c (%) 5.1 ± 0.3 5.4 ± 0.2 0.380
D-dimer (μg/mL) 0.77 ± 0.46 0.69 ± 0.39 0.385
Echocardiography
TRPG (mm Hg) 68.6 ± 29.9 76.6 ± 27.6 0.468
TAPSE (mm) 17.4 ± 3.9 19.6 ± 6.3 0.357
PE, n (%) 0 (0%) 2 (17%) 0.166
Exercise capacity
6MWD 374 ± 155 446 ± 45 0.048
Cardiac catheterization
PAWP (mm Hg) 10.8 ± 4.5 10.6 ± 3.1 0.898
Systolic PAP (mm Hg) 75.4 ± 28 80.2 ± 15.3 0.562
Diastolic PAP (mm Hg) 32.1 ± 12.2 27.1 ± 6.9 0.168
Mean PAP (mm Hg) 50 ± 17 49 ± 9 0.955
PVR (dyne/s/cm5) 908 ± 674 619 ± 251 0.121
RAP (mm Hg) 6.3 ± 4.8 7.8 ± 3.3 0.344
SvO2 (%) 68.3 ± 9.4 66.2 ± 7.1 0.515
CO (L/min) 4.57 ± 1.48 5.47 ± 1.57 0.134
CI (L/min/m2) 2.99 ± 0.94 3.11 ± 0.81 0.718
PAH: pulmonary arterial hypertension; CTEPH: chronic thromboembolic pulmonary
hypertension; BMI: body mass index; IPAH: idiopathic pulmonary arterial hypertension;
CTD: collagen tissue disease; PPH: portopulmonary hypertension; CHD: congenital heart
disease; BNP: brain natriuretic peptide; BP: blood pressure; RVP: right ventricular
pressure; TRPG: transpulmonary pressure gradient; TAPSE: tricuspid annular plane
systolic excursion; UA: uric acid; eGFR: estimated glomerular ﬁltration rate; T.
chol: total cholesterol; PE: pericardial effusion; 6MWD: 6-min walking distance; PAWP:
pulmonary artery wedge pressure; PAP: pulmonary arterial pressure; PVR: pulmonary
vascular resistance; RAP: right atrial pressure; SvO2: mixed venous oxygen saturation;
CO: cardiac output; and CI: cardiac index.
398 A. Hirashiki et al. / Life Sciences 118 (2014) 397–403Sherrill, 1998). In fact, a recentmeta-analysis showed that the improve-
ment of the 6MWDdid not correlatewith the outcomes in patientswith
PAH (Savarese et al., 2012). On the other hand, Wensel et al. demon-
strated that the CPX could be useful; patients who had a peak oxygen
uptake (peak VO2) b10.4 mL/min/kg had a worse prognosis than
patients who were able to clear these thresholds (Wensel et al., 2002).
There has been increasing recognition of the potential value of CPX to
monitor patients with pulmonary hypertension (PH) (Arena et al.,
2010; Triantafyllidi et al., 2010). Despite such detailed recommenda-
tions (Palange et al., 2007; Ross, 2003), no standard protocol of CPXTable 2
Parameters of laboratory measurements, echocardiograms and the CPX at baseline and after b
PAH p (p
Baseline After bosentan
Plasma BNP (pg/mL) 187 ± 288 54 ± 98 0.09
UA (mg/dL) 6.6 ± 2.6 5.6 ± 1.8 0.07
TRPG (mm Hg) 68.6 ± 29.9 48.4 ± 23.4 0.00
TAPSE (mm) 17.4 ± 3.9 19.2 ± 4.1 0.30
VE/VCO2 slope 55.3 ± 21.6 45.7 ± 16.7 0.02
ΔVO2/ΔWR 5.1 ± 3.8 7.1 ± 3.4 0.06
CPX: cardiopulmonary exercise testing; WR: work rate; other abbreviations as in Table 1.with respect to the management of patients with PH has been
established. Moreover, there is limited data about the effects of
bosentan on exercise capacity determined by the CPX in patients with
PAH and CTEPH (Zhai et al., 2011). Therefore, the main purpose of this
studywas to investigate the effects of an oral dual ERA, bosentan, on ex-
ercise capacity using CPX in patients with PAH and inoperable CTEPH.
Materials and methods
Study design and population
This study was conducted retrospectively in a single center from
September 2009 to June 2013. Patients between 16 and 80 years old
at the entry to the study who had a clinical diagnosis of PAH or inoper-
able CTEPH based on the Dana point criteria (Simonneau et al., 2009)
and a current status of PAH based on the World Health Organization
functional classes (WHO-FC) from II to IV were enrolled in the study.
Patients with the following conditions were excluded: (1) groups 2,
3, and 5 of Dana point classiﬁcation of PAH; (2) pregnancy; (3) serum
creatinine N2.0 mg/dL; (4) history of serious chronic obstructive pul-
monary disease or restrictive lung disease (%VC b70%); (5) unable to
walk without personal aid; (6) PAH-targeted therapy, such as another
ERA, phosphodiesterase V inhibitor or intravenous epoprostenol al-
ready being taken; and (7) other conditions which the physicians in
charge judged to be contraindications due to any safety concerns.
The interval between the diagnosis of CTEPH and study entry was
more than three months in all patients. All patients underwent stan-
dardized assessments, including ventilation/perfusion scanning, helical
CT scanning of the chest and pulmonary angiography. In patients with
inoperable CTEPH, the inclusion criteria for this study were as follows:
(1) CTEPH judged to be inoperable by an experienced surgeon and car-
diologists because of the peripheral location of the vascular obliteration;
(2) hemodynamic evaluation showing precapillary pulmonary hyper-
tension (pulmonary capillary wedge pressure [PCWP] b15 mm Hg),
with a mean pulmonary arterial pressure (mPAP) N25 mm Hg.
The study protocol was approved by the Ethics Review Board of the
Nagoya University School of Medicine (No. 1157). All participants pro-
vided their written informed consent after receiving explanations by a
physician in charge about the study objectives, study protocol, possible
adverse effects of the study drugs, measures for privacy protection and
study withdrawal.
Study procedures
Patients with newly diagnosed PAH or CTEPH in WHO-FC II, III, and
IV received the oral dual ERA, bosentan. Bosentan was given at a dose
of 62.5 mg twice daily for 4 weeks, followed by 125 mg twice daily,
thereafter. Liver function tests were performed at four-week intervals,
and elevation of the transaminase levels was handled according to the
product information included for bosentan. Patients in WHO-FC IV
with hemodynamic instability were immediately treated withosentan treatment.
aired-t) CTEPH p (paired-t)
Baseline After bosentan
2 101 ± 128 69 ± 82 0.067
9 6.8 ± 2.3 6.4 ± 2.4 0.156
3 76.6 ± 27.6 67.7 ± 32.4 0.211
8 19.6 ± 6.3 20.6 ± 5.1 0.317
4 47.2 ± 14.4 41.9 ± 15.5 0.238
4 7.8 ± 3.4 8.5 ± 2.5 0.178
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399A. Hirashiki et al. / Life Sciences 118 (2014) 397–403intravenous epoprostenol if needed. Patients were always informed
about all available treatment options. All drug regimens were individu-
ally adjusted if necessary to limit side effects.
Measurements of interest
Demographic variables such as the sex, age, smoking status, comor-
bidities, drugs and toxins, connective tissue diseases, HIV infection, por-
tal hypertension, congenital heart disease and chronic hemolytic
anemia were obtained at baseline. In addition, physical, laboratory and
physiological ﬁndings, including anthropometry data, blood pressure,
WHO-FC, blood examinations, electrocardiograms, echocardiograms,
respiratory function tests, CPX and right heart catheterization were
evaluated at baseline. The above measurements were repeated three
to six months after the entry, except for the respiratory function tests
and right heart catheterization. The blood examination included the fol-
lowing items: plasma brain natriuretic peptide (BNP), uric acid, blood
urea nitrogen, serum creatinine, sodium, potassium and liver enzyme
levels, including alanine aminotransferase, aspartate aminotransferase,
γ-glutamyl transpeptidase and the bilirubin level.
Exercise capacity
Each patient underwent CPX at a progressively increasing work rate
to maximum tolerance on a cycle ergometer. The test protocol was in
accordance with the recommendations of the American Thoracic Socie-
ty and the American College of Chest Physicians (Ross, 2003). Oxygen
and carbon dioxide sensors were calibrated before each test by using
gasses with known oxygen, nitrogen and carbon dioxide concentra-
tions. A ﬂow sensor was also calibrated before each test. All patients
started at 10W for a 3-minwarm-up, followed by a 10-W/min ramp in-
crement protocol. The 12-lead electrocardiogram was monitored con-
tinuously, and the blood pressure was measured every minute during
exercise and throughout the recovery period. After achieving the peak
workload, all patients pedaled at a load of 0 W for a cool-down period
of at least 2 min to prevent excess venous pooling. The test termination
criteria consisted of patient request, volitional fatigue, ventricular tachy-
cardia,≥2mmof horizontal or down-sloping ST segment depression or
a drop in systolic blood pressure of≥20mmHgduring exercise. A qual-
iﬁed exercise physiologist conducted each test, with a certiﬁed
cardiologist's supervision. Respiratory gas exchange variables, including
the oxygen uptake (VO2), carbon dioxide output (VCO2) and minute
ventilation (VE), were acquired continuously throughout the exercise
test using an Ergospirometry Oxycon Pro (Carefusion Germany, 234,
GmbH, Höchberg, Germany), and the gas-exchange data were obtained
breath-by-breath. The peakVO2was expressed as the highest 30-s aver-
age value obtained during the last stage of the exercise test, and the
peak respiratory exchange ratio (RER) was the highest 30-s average
value during the last stage of the test. The VE/VCO2 slope was deter-
mined by using a linear regression analysis of the VE and VCO2 obtained
during exercise. The parameters of CPX included the following items:
peak VO2, VE/VCO2 slope, ΔVO2/ΔWR (work rate), peak systolic blood
pressure and peak heart rate.
Statistical analysis
All data are expressed as means ± SD. For differences in the mea-
surements between the PAH and CTEPH groups, normally distributed
variables were compared by Student's t-test, non-normally distributed
variables by the Mann–Whitney U test and categorical variables were
assessed by the Chi-squared analysis. To evaluate the effects of
bosentan, hemodynamic parameters at baseline and those after
bosentan therapy were compared by paired t-tests. Changes from base-
line in the peak VO2, VE/VCO2 slope, tricuspid regurgitation pressure
gradient (TRPG), and plasma BNP were assessed between the PAH and
CTEPH groups by unpaired t-tests. Correlations were evaluated with
Table 4
Parameters during CPX at rest, AT and peak for CTEPH patients.
CTEPH
Rest p (paired-t) AT p (paired-t) Peak p (paired-t)
Baseline After bosentan Baseline After bosentan Baseline After bosentan
VO2 (mL/min/kg) 6.0 ± 1.4 6.4 ± 2.1 0.891 11.5 ± 3.6 11.6 ± 4.0 0.767 16.2 ± 5.1 16.5 ± 5.8 0.714
O2 pulse 3.3 ± 1.0 3.3 ± 1.2 0.712 4.7 ± 1.5 4.8 ± 1.7 0.644 7.7 ± 2.7 8.5 ± 3.5 0.126
Heart rate (bpm) 79 ± 14 75 ± 8 0.308 111 ± 17 107 ± 11 0.468 142 ± 19 134 ± 16 0.089
SBP (mm Hg) 121 ± 24 121 ± 18 0.910 141 ± 31 146 ± 24 0.546 160 ± 35 174 ± 27 0.150
RER 0.81 ± 0.13 0.78 ± 0.10 0.475 0.94 ± 0.07 0.94 ± 0.09 0.941 1.10 ± 0.09 1.08 ± 0.13 0.798
PETCO2 (mm Hg) 26.5 ± 4.1 29.3 ± 10.7 0.290 25.8 ± 4.6 29.8 ± 9.8 0.119 23.9 ± 5.2 29.3 ± 10.7 0.040
Abbreviation as in Table 3.
400 A. Hirashiki et al. / Life Sciences 118 (2014) 397–403the Pearson correlation test. All statistical analyses were performed
using the SPSS 17.0 software package (SPSS Inc., Chicago, IL, USA). A p
value b0.05 was considered to be statistically signiﬁcant.
Results
In total, 17 consecutive PAH (46 ± 21 years) and 12 consecutive in-
operable CTEPH (49±11 years) patientswithWHO-FC II to IVwere en-
rolled in this study. At 6 months, 15 (88%) of the PAH and 11 (92%)
of the CTEPH patients were taking the maximum dose of bosentan
(125 mg two times daily), with two (12%) and one (8%) patient in the
respective group taking bosentan at 62.5 mg twice daily. Bosentan
was tolerated by all patients, and there was no evidence of drug-
related liver dysfunction. There were no accidents during CPX in either
of the groups. The baseline characteristics of the subjects are shown in
Table 1. The mean age and gender did not differ between the two
groups. The body mass index was signiﬁcantly lower in the PAH group0
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PAH
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Fig. 1. The effects of bosentan therapy on A) the peak VO2 in PAH patients, B) the peak VO2 in
baseline value, right: values after six months of bosentan therapy in individual patients.than in the CTEPH group. There were no signiﬁcant differences in the
plasmaBNP, uric acid, hemoglobin, total cholesterol, triglyceride, hemo-
globin A1c, D-dimer, TRPG, mPAP, pulmonary vascular resistance (PVR),
mixed venous oxygen saturation, cardiac output or cardiac index be-
tween the PAH and CTEPH patients. There were no signiﬁcant changes
in these laboratory measurements before and after bosentan therapy
in both the groups (data not shown). 6MWD was signiﬁcantly shorter
in the PAH group than in the CTEPH group.
The parameters of laboratory measurements, echocardiograms and
CPX at baseline and after bosentan therapy are shown in Table 2. In
the PAH group, the TRPG and VE/VCO2 slope signiﬁcantly decreased
from baseline to after bosentan therapy (p = 0.003 and p = 0.024, re-
spectively). The plasma BNP, uric acid and ΔVO2/ΔWR tended to im-
prove after bosentan therapy (p = 0.092, p = 0.079 and p = 0.064,
respectively).
In contrast, in CTEPH patients, the plasma BNP tended to decrease
from baseline after bosentan therapy, but not signiﬁcantly (p =0
10
20
30
baseline after bosentan
baseline after bosentan
Peak VO2
CTEPH
(mL/min/kg)
P=0.714
0
10
20
30
40
50
Peak PETCO2
CTEPH
(mmHg) P=0.040
B
D
CTEPH patients, C) the PETCO2 in PAH patients and D) the PETCO2 in CTEPH patients. Left:
02
4
6
8
0.0
1.0
2.0
3.0
4.0
5.0
PAH CTEPHPAH CTEPH
-30
-20
-10
0
PAH CTEPH
P=0.068
(mL/min/kg)
(mmHg)
(mmHg)
P=0.037
Ch
an
ge
 fr
om
 b
as
el
in
e
in
 p
ea
k 
VO
2
Ch
an
ge
 fr
om
 b
as
el
in
e
in
 p
ea
k 
PE
TC
O
2
Ch
an
ge
 fr
om
 b
as
el
in
e
in
 T
R
PG
 
P=0.41
-160
-120
-80
-40
0
PAH CTEPH
P=0.20(pg/mL)
Ch
an
ge
 fr
om
 b
as
el
in
e
in
 p
la
sm
a 
BN
P 
le
ve
l 
A B
DC
Fig. 2. The change from baseline to after bosentan therapy in A) the peak VO2, B) VE/VCO2 slope, C) tricuspid regurgitation pressure gradient (TRPG), and D) plasma BNP level. The data are
presented as the means ± SEM. Blue: baseline values, yellow: values after bosentan therapy.
401A. Hirashiki et al. / Life Sciences 118 (2014) 397–4030.067). The other parameters, including uric acid level and echocar-
diograms, did not differ between the baseline and after bosentan
therapy.
The CPXparameters during exercise are shown for the PAH (Table 3)
and CTEPH (Table 4) patients. The CPX parameters at rest, anaerobic
threshold, and peak at the baseline and after bosentan therapy were
not signiﬁcantly different between the PAH and CTEPH groups, except
for the O2 pulse at rest and baseline (Table 3). Fig. 1 shows the changes
in the peak VO2 and PETCO2 between the baseline and after bosentan
therapy in the PAH and CTEPH groups. In PAH patients, the peak VO2
signiﬁcantly increased from 13.5 ± 5.7 at baseline to 16.7 ± 6.8 after
bosentan therapy (p = 0.009). The PETCO2 at rest and anaerobic
threshold were signiﬁcantly increased after bosentan therapy (p =
0.029 and p = 0.044, respectively). The response of the heart rate and
systolic blood pressure did not differ between the baseline and after
bosentan therapy.
In contrast, in CTEPH patients, there were no signiﬁcant differences
in exercise capacity, including peak VO2, VE/VCO2 slope, O2 pulse and
ΔVO2/ΔWR between the baseline and after bosentan therapy
(Tables 2 and 4). Only the peak PETCO2 was signiﬁcantly increased
after bosentan therapy from baseline (p = 0.040). In addition, the
peak heart rate tended to decrease after bosentan therapy from baseline
(p = 0.089). Fig. 2 shows the changes from baseline after bosentan
therapy in the peak VO2, PETCO2, TRPG and plasma BNP. The change
in the peak VO2 was signiﬁcantly larger in the PAH group than in the
CTEPH group (mean ± SEM, 3.14 ± 1.06 mL/kg/min vs. 0.28 ±
0.75 mL/kg/min; p = 0.037), and the change in the TRPG tended to be
larger in the PAH compared to the CTEPH group, but the differencewas not signiﬁcant (−25.93 ± 5.97 mm Hg vs.−8.85 ± 6.66 mm Hg;
p = 0.068). There were no signiﬁcant differences in the change
from baseline in the PETCO2 and plasma BNP level between the
PAH and CTEPH groups (3.08 ± 1.64 vs. 5.47 ± 2.35; p = 0.41 and
−132.68± 73.91 pg/mL vs.−32.03± 15.76 pg/mL; p= 0.20, respec-
tively). Fig. 3 shows the correlation between PVR and the change from
baseline in peak VO2. In PAH, the change from baseline in peak VO2
was correlated with PVR (r = 0.489, p = 0.046), on the other hand, in
CTEPH, there were no correlation between them (r= 0.060, p= 0.85).
Discussion
The present study demonstrated that CPX is useful for assessing ex-
ercise capacity of patients with inoperable CTEPH under the treatment
with an ERA. In CTEPH patients, the peak PETCO2 signiﬁcantly increased
from baseline after the bosentan therapy, while there were no signiﬁ-
cant improvements in the peakVO2 or VE/VCO2 slope after the bosentan
therapy. In addition, the plasma BNP and the peak heart rate during ex-
ercise tended to decrease after bosentan therapy. The data suggest that
bosentan therapy improved partially the exercise capacity in patients
with inoperable CTEPH demonstrated by an improvement of peak
PETCO2 but not peak VO2. The bosentan treatment was well tolerated
by all patients, and there was no evidence of drug-related liver dysfunc-
tion in both groups during the follow-up period. In addition, there were
no accidents during the CPX. We herein report, for the ﬁrst time, the
therapeutic effects of bosentan on the peak VO2, VE/VCO2 slope,
PETCO2, and peak heart rate determined by CPX in patientswith inoper-
able CTEPH compared to PAH.
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Fig. 3.Correlation of pulmonary vascular resistance (PVR) and the change from baseline in
peak VO2 in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmo-
nary hypertension (CTEPH). Simple linear regressions are shown for PAH (blue line) and
CTEPH (green dotted line). Correlation coefﬁcients (r) and p values for each relationship
are indicated.
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The current treatment algorithms for PAH (Galie et al., 2009;
McLaughlin et al., 2009) recommend using an ERA or phosphodiester-
ase type-5 inhibitor as ﬁrst-line treatment for PAH in WHO-FC II or III
froma relatively early stage of PAH.However, there has been little infor-
mation available about the therapeutic effects of bosentan on the exer-
cise capacity determined by the CPX in PAH and CTEPH patients.
In PAH, the PVR was decreased and clinical improvement was ob-
served by bosentan treatment (Channick et al., 2001). In contrast, the ef-
fects of bosentan treatment have been unclear in CTEPH patients.
Several uncontrolled clinical studies suggested that ERAs may provide
hemodynamic and clinical beneﬁts in patients with CTEPH (Hoeper
et al., 2005a; Hughes et al., 2005). However, one randomized, placebo-
controlled clinical trial, the BENEFIT study, which has addressed the
safety and efﬁcacy of targeted medical treatment, revealed a signiﬁcant
drop in the PVR in the bosentan group, but no change in the 6MWD,
WHO-FC or time to clinical worsening in patients with inoperable
CTEPH during a 16-week period (Jais et al., 2008). In a previous meta-
analysis, bosentan therapywas found to be associatedwith an improve-
ment of the hemodynamics and exercise capacity in patients with
CTEPH (Becattini et al., 2010).Exercise capacity determined by the CPX
Most investigations of PAH or CTEPH have focused on the cardiac
function at rest. In addition, the therapeutic effects on the exercise ca-
pacity for PH patients were commonly based on the 6MWD. However,
in a recent meta-analysis of the 6MWD in patients with PAH, the im-
provement in the 6MWD did not reﬂect a beneﬁt in terms of the clinical
outcomes (Savarese et al., 2012). One of the main reasons is that the
6MWD depends not only on the cardiopulmonary function, but also
on other factors, including the sex, body weight and height (Enright
and Sherrill, 1998). In addition, to our knowledge, there were few data
to investigate the effect of exercise capacity determined by CPX on
bosentan therapy in patients with CTEPH (Zhai et al., 2011).In the present study, peak VO2 was signiﬁcantly improved in PAH
patients compared with CTEPH patients (Fig. 2). In addition, the
PETCO2 at rest and the anaerobic threshold improved signiﬁcantly
after the bosentan therapy in PAH patients, in accordance with a previ-
ous study (Yasunobu et al., 2005). Moreover, only in PAH, the change
from baseline in peak VO2 was correlated with PVR, suggesting that
the effect of bosentan on exercise capacity might be improved in more
severe PAH. The mechanism remains unclear. Further investigations
are needed.
On the other hand, in the CTEPH group, therewere no signiﬁcant dif-
ferences in the main parameters of biomarker levels, echocardiography
or exercise capacity after the bosentan therapy. However, the peak
PETCO2 signiﬁcantly increased after the bosentan therapy in the
CTEPH patients. These results suggested that the bosentan partially im-
proved cardiopulmonary function during exercise despite similar levels
of hemodynamic parameters in theCTEPHpatients. The reduction in the
PETCO2 seen in the PAH or CTEPH patients may be explained by an in-
crease in the physiological dead space/tidal volume and/or a decrease
in the ideal alveolar PaCO2 (Reybrouck et al., 1998). CTEPH patients
may have vasculopathy at the pre-capillary level beyond obstructive
thrombotic lesions. It is such a resistive component that is most likely
responsive to medical therapy in CTEPH patients (Fedullo et al., 2001).
Moreover, plasma BNP level and peak heart rate tended to decrease
after the bosentan therapy in CTEPH patients. In both PAH and CTEPH,
the gas exchange and cardiac function during exercise could be poten-
tially improved by the bosentan therapy. However, the main parame-
ters by the CPX, including the peak VO2, VE/VCO2 slope, and O2 pulse
did not improved signiﬁcantly in patients with CTEPH. The effects of
bosentan on exercise capacity were limited in patients with CTEPH.
It has been reported that orally applied bosentan increased plasma
endothelin-1 by 2-fold in humans (Weber et al., 1996). A blocking of
the ET-B receptors decreases in clearance of plasma endothelin-1, there-
by resulting in bosentan therapy increasing plasma endothelin-1 level
in humans: this phenomenonwould be a reason for notmeasuring plas-
ma endothelin level in various manuscripts in patients with PH (Galie
et al., 2008; Rubin et al., 2002). Therefore, in the current study, we did
not measure plasma endothelin-1 level. On the other hand, because
Hiramoto et al. reported that the intensity of increase in plasma
endothelin-1 level by bosentan at the acute phase (24 h after oral ad-
ministration) may be a predictor of responsiveness of efﬁciency of
bosentan in PAH patients (Hiramoto et al., 2009), it is likely that a mea-
surement of plasma endothelin-1 at the initial phase of bosentan thera-
py would be useful in the treatment of drugs in the PAH patients.
There are several limitations to our study. First, this study was per-
formed in a small number of patients and had short follow-up periods.
Second, the assessment of peripheral factors was not performed.
Third, this study was an open-label design, which could affect the re-
sults of the 6MWD, and that of peak VO2 in CPX. However, the results
of VE/VCO2 slope and PETCO2 are less dependent on the will of patients
examined. Controlled protocols on the mortality and time to clinical
worsening in patients with CTEPH are needed.Conclusion
While bosentan therapy improved the peak PETCO2 but not the peak
VO2 in patients with inoperable CTEPH, it improved the peak VO2 and
VE/VCO2 slope in patients with PAH. The increase of peak PETCO2 in
CTEPH might reﬂect the increase of cardiac output during exercise by
the bosentan therapy. On the other hand, ventricular efﬁciency was dif-
ferent between PAHandCTEPHbecause of the effect of thromboembolic
vascular occlusion on physiologic dead space fraction. These results
should be interpreted with caution in the present study. The present
study demonstrated that CPX is useful for assessing the exercise capac-
ity of patients with PAH and inoperable CTEPH under the treatment
with an ERA.
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